ReShape Lifesciences reported Q1 2025 financial results, highlighting a reverse stock split, patent approvals, and a merger agreement with Vyome. Effective execution of a 1-for-25 reverse stock split, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results